|Assessment Status||Rapid Review Complete|
|Indication||Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).|
|Rapid review commissioned||10/02/2015|
|Rapid review completed||13/04/2015|
|Rapid review outcome||Full Pharmacoeconomic Evaluation not Recommended|
Naloxegel (Moventiq®) is to be reimbursed under the Community Drugs Schemes subject to conditions.